SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
User experienced gynecomastia from finasteride and found a solution using liposomal topical finasteride. This method minimizes side effects and is effective for hair loss treatment.
Creating a propylene glycol-free Minoxidil and Tretinoin solution to reduce skin irritation and enhance effectiveness. An emulsifier like lecithin can help mix Tretinoin properly, and Minoxidil foam is an alternative without propylene glycol.
A 19-year-old male switched from finasteride and minoxidil to dutasteride due to continued hair thinning and is experiencing increased nipple sensitivity and a small lump, raising concerns about gynecomastia. Suggestions include slowing the transition, checking hormone levels, and considering an aromatase inhibitor.
Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.
A user shared their hair regrowth progress using oral finasteride, biotin, topical minoxidil, and DS thickening shampoo over five months, reporting significant improvements in hair texture and growth. They experienced minor side effects like a slight headache from switching minoxidil forms but noted no issues with finasteride.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.
The conversation discusses the potential benefits of castor oil for hair thickening, with one user noting it may increase prostaglandin E2 and decrease PGD2. The original poster plans to take 1-2ml orally daily.
The user experienced increased shedding and side effects like oily skin and acne after switching from finasteride to dutasteride, despite initially having success with finasteride. They also tried oral spironolactone, which reduced libido but didn't help with hair loss, and are considering returning to finasteride only.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
Sulfur soap may help with hair thickening and reducing scalp inflammation, but it can cause dryness. Nizoral, containing ketoconazole, is noted for its potential to reduce seborrheic dermatitis but may also cause scalp dryness and hair loss.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.
User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
A 22-year-old is experiencing increased hair shedding and a greasy scalp after two months on 1mg finasteride. They are documenting their progress and seeking advice, with feedback suggesting that shedding is normal and results may take 6-12 months.
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
A user shared their experience with finasteride, reporting severe side effects like erectile dysfunction and watery semen, which improved after stopping the medication. They emphasized the risks of finasteride and decided not to resume its use despite hair loss stabilization.
A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.